Complementary value of electron microscopy and immunohistochemistry in the diagnosis of non-small cell lung cancer: A potential role for electron microscopy in the era of targeted therapy.

Adenocarcinoma (ADC) Electron microscopy (EM) Immunohistochemistry (IHC) Non-small cell lung carcinoma Not otherwise specified (NSCLC-NOS) Squamous Cell Carcinoma (SCC) Targeted therapy

Journal

Ultrastructural pathology
ISSN: 1521-0758
Titre abrégé: Ultrastruct Pathol
Pays: England
ID NLM: 8002867

Informations de publication

Date de publication:
2019
Historique:
pubmed: 8 12 2019
medline: 25 8 2020
entrez: 8 12 2019
Statut: ppublish

Résumé

With the identification of therapeutic targets for lung adenocarcinoma, it has become mandatory to distinguish it from other entities. Some cases remain classified as non-small cell lung carcinoma, not otherwise specified (NSCLC-NOS) with immunohistochemistry. Electron microscopy (EM) can be useful, allowing the identification of glandular differentiation. The aim of this study was to determine the complementary value of immunohistochemistry and EM.Forty-eight NSCLC-NOS cases were selected (PSMAR-Biobank, Barcelona, Spain). Immunohistochemistry (TTF-1, p40) was performed. Tissue was retrieved from paraffin blocks. Results were compared to the final diagnosis, derived from combination of light microscopy, immunohistochemistry, EM, molecular studies and resection specimen.Immunohistochemistry concurred with final diagnosis in 36 cases (75%, Kappa = 0.517). EM agreed with final diagnosis in 35 (72.9%, Kappa = 0.471). Immunohistochemistry had a sensitivity = 73%, specificity = 100%, positive predictive value (PPV) = 100% and negative predictive value (NPV) = 52.4% for adenocarcinoma. All adenocarcinoma cases not solved by immunohistochemistry (n = 10) were classified by EM, and vice versa. Data from EM were identical to those of immunohistochemistry: sensitivity = 73%, specificity = 100%, PPV = 100% and NPV = 52.4%. Combining both techniques, 47 cases were coincident with final diagnosis (97.9%, Kappa = 0.943).EM can provide valuable information in subtyping NSCLC-NOS, being particularly useful when immunohistochemistry is inconclusive. EM could be considered as a complementary tool for decision-making in NSCLC-NOS.

Identifiants

pubmed: 31810413
doi: 10.1080/01913123.2019.1692118
doi:

Substances chimiques

Biomarkers, Tumor 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

237-247

Auteurs

Raquel Albero-González (R)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Jessica Munné-Collado (J)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Lara Pijuan (L)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Mercedes Simón (M)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Javier Gimeno-Beltrán (J)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Sergi Mojal (S)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Marta Salido (M)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Sergi Clavé (S)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Nuria Juanpere (N)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Alba Dalmases (A)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Laura Comerma (L)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Ivonne Vázquez (I)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Albert Sánchez-Font (A)

Universitat Autònoma de Barcelona, Barcelona, Spain.
Department of Pneumology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Álvaro Taus (Á)

Department of Oncology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.

Silvia Hernández (S)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain.

Belén Lloveras (B)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Universitat Autònoma de Barcelona, Barcelona, Spain.

Josep Lloreta Trull (J)

Department of Pathology, Hospital del Mar - Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain.
Department of Health and Experimental Sciences, Universitat Pompeu Fabra, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH